- Benzinga•18 hours ago
Piper Jaffray reiterated its Overweight rating and $106 target price on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) despite discontinuation of ENDEAVOUR trial of Revusiran as it sees value in the company’s ...
- 24/7 Wall St.•2 days agoFamous Investor Continues Large Insider Buying: Lands’ End, Cree, Alnylam Pharmaceuticals, Cheniere Energy and More
Here are some of the companies that reported notable insider buying last week, including Cheniere Energy and Lands' End.
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||37.39 x 200|
|Ask||37.49 x 100|
|Day's Range||37.15 - 37.85|
|52wk Range||33.16 - 110.75|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-8.90|
|Avg Vol (3m)||1,168,432|
|Dividend & Yield||N/A (N/A)|